We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > eVLP

News List

Novel COVID-19 vaccine shows promise in Canadian trial europeanpharmaceuticalreview
July 05, 2021
Phase I data shows VBI-2902a induced neutralisation and antibody titres up to five times that of people who had recovered from COVID-19 infection.
CEPI and VBI to develop vaccines against SARS-CoV-2 variants pharmaceutical-technology
March 12, 2021
The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines have entered a collaboration to advance the latter’s enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants.
VBI Vaccines begins enrolment in Covid-19 vaccine candidate study pharmaceutical-technology
March 11, 2021
VBI Vaccines has commenced enrolment in an adaptive Phase I/II clinical study of its enveloped virus-like particle (eVLP) Covid-19 vaccine candidate, VBI-2902.